ACTRAPID HM PENFILL

Description

ACTRAPID HM PENFILL is a formulation of human insulin (regular insulin) that provides rapid control of blood glucose levels in individuals with Type 1 or Type 2 diabetes. The “HM” in ACTRAPID HM stands for “human insulin,” indicating that the insulin is identical to the naturally occurring insulin in the human body.

Key Features:

• Rapid-acting insulin: It begins to lower blood glucose levels within 30 minutes of injection, peaks at approximately 2-3 hours, and continues to work for 5-8 hours.

• Pre-filled cartridge: ACTRAPID HM PENFILL is supplied in a 3mL cartridge that is designed for use with insulin pens, providing ease and flexibility in administering insulin.

• Convenient for use with insulin pens: The PENFILL cartridge is used with compatible insulin pens (like the NovoPen), making it easy to measure and inject the right dose of insulin.

• Use before meals: It is typically used to control blood sugar levels during or after meals, as it helps to manage the blood sugar spikes that occur after eating.

How It Works: ACTRAPID HM is a short-acting insulin that works by helping glucose (sugar) enter the body’s cells, where it can be used for energy. It also helps the liver stop producing too much glucose. This insulin mimics the rapid action of natural insulin released in response to meals.

The insulin is injected subcutaneously (under the skin) and is generally used in combination with other insulins or oral medications as part of a comprehensive diabetes management plan.

Administration and Dosage: ACTRAPID HM PENFILL is injected subcutaneously into fatty tissue, usually in the abdomen or thigh. The exact dosage and timing depend on the patient’s individual needs, as determined by their healthcare provider. It is typically injected before meals to help control the rise in blood sugar that occurs after eating.

Dosage adjustments may be needed based on:

• Blood glucose levels

• Activity level

• Diet

It’s important to follow the dosing schedule provided by the healthcare provider, as improper dosing can lead to hypo- or hyperglycemia.